Total Payments
$235.20
2023 Payments
$82.62
Companies
5
Transactions
11
Medicare Patients
2,036
Medicare Billing
$126,814
Payment Breakdown by Category
Food & Beverage$160.21 (68.1%)
Education$74.99 (31.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $160.21 | 10 | 68.1% |
| Education | $74.99 | 1 | 31.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $121.46 | 7 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $62.88 | 1 | $0 (2023) |
| Coloplast Corp | $19.74 | 1 | $0 (2023) |
| Cogentix Medical Inc. | $15.86 | 1 | $0 (2017) |
| Boston Scientific Corporation | $15.26 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $82.62 | 2 | AstraZeneca Pharmaceuticals LP ($62.88) |
| 2019 | $15.26 | 1 | Boston Scientific Corporation ($15.26) |
| 2018 | $12.35 | 1 | Astellas Pharma US Inc ($12.35) |
| 2017 | $124.97 | 7 | Astellas Pharma US Inc ($109.11) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/02/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $62.88 | General |
| Category: Oncology | ||||||
| 02/08/2023 | Coloplast Corp | SpeediCath (Device) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Continence Care | ||||||
| 03/22/2019 | Boston Scientific Corporation | ACCUMAX (Device) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: LITHOTRIPSY | ||||||
| 05/16/2018 | Astellas Pharma US Inc | VESICARE (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: UROLOGY | ||||||
| 12/06/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare, Xtandi | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Urology | ||||||
| 12/05/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $74.99 | General |
| 10/04/2017 | Cogentix Medical Inc. | Urgent PC (Device), Macroplastique, PrimeSight | Food and Beverage | Cash or cash equivalent | $15.86 | General |
| Category: Urology | ||||||
| 08/31/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare, Xtandi | Food and Beverage | In-kind items and services | $4.71 | General |
| Category: Urology | ||||||
| 04/06/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: Urology | ||||||
| 03/16/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare, Xtandi | Food and Beverage | In-kind items and services | $2.94 | General |
| Category: Urology | ||||||
| 03/02/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare, Xtandi | Food and Beverage | In-kind items and services | $3.53 | General |
| Category: Urology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 9 | 649 | 846 | $99,469 | $29,940 |
| 2021 | 13 | 1,191 | 1,640 | $250,139 | $87,847 |
| 2020 | 4 | 196 | 219 | $24,529 | $9,026 |
Total Patients
2,036
Total Services
2,705
Medicare Billing
$126,814
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 184 | 263 | $41,912 | $14,419 | 34.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 131 | 131 | $25,667 | $7,383 | 28.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 32 | 36 | $20,628 | $5,449 | 26.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $2,772 | $1,113 | 40.2% |
| 81003 | Automated urinalysis test | Office | 2022 | 225 | 330 | $2,640 | $736.07 | 27.9% |
| 51700 | Simple bladder irrigation and/or instillation | Office | 2022 | 11 | 11 | $2,574 | $454.24 | 17.6% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2022 | 29 | 31 | $1,643 | $202.39 | 12.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 12 | 16 | $576.00 | $124.34 | 21.6% |
| 81002 | Urinalysis, manual test | Office | 2022 | 14 | 17 | $1,057 | $57.97 | 5.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 188 | 304 | $40,128 | $19,674 | 49.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 178 | 178 | $53,400 | $18,118 | 33.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 182 | 182 | $35,490 | $13,946 | 39.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 116 | $22,620 | $10,820 | 47.8% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 61 | 66 | $37,818 | $10,622 | 28.1% |
| 52356 | Crushing of stone in urinary duct (ureter) with stent using an endoscope | Facility | 2021 | 16 | 17 | $20,689 | $5,411 | 26.2% |
| 55700 | Biopsy of prostate gland | Office | 2021 | 14 | 15 | $10,500 | $2,624 | 25.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 24 | 25 | $6,300 | $2,605 | 41.3% |
| 81003 | Automated urinalysis test | Office | 2021 | 357 | 637 | $5,096 | $1,423 | 27.9% |
| 52332 | Insertion of stent in urinary duct (ureter) using an endoscope | Facility | 2021 | 12 | 12 | $11,676 | $1,008 | 8.6% |
| 51700 | Bladder irrigation and/or instillation | Office | 2021 | 12 | 13 | $3,042 | $722.70 | 23.8% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 29 | 35 | $1,260 | $582.08 | 46.2% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2021 | 33 | 40 | $2,120 | $291.33 | 13.7% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 90 | 90 | $18,340 | $7,026 | 38.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 25 | $3,516 | $1,384 | 39.4% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 11 | 11 | $1,929 | $410.13 | 21.3% |
About Dr. Richard Mynatt, MD
Dr. Richard Mynatt, MD is a Urology healthcare provider based in Sunnyside, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568487627.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Mynatt, MD has received a total of $235.20 in payments from pharmaceutical and medical device companies, with $82.62 received in 2023. These payments were reported across 11 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($160.21).
As a Medicare-enrolled provider, Mynatt has provided services to 2,036 Medicare beneficiaries, totaling 2,705 services with total Medicare billing of $126,814. Data is available for 3 years (2020–2022), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology, Urology
- Location Sunnyside, WA
- Active Since 07/12/2006
- Last Updated 03/07/2025
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1568487627
Products in Payments
- LYNPARZA (Drug) $62.88
- Myrbetriq (Drug) $34.12
- SpeediCath (Device) $19.74
- Urgent PC (Device) $15.86
- ACCUMAX (Device) $15.26
- VESICARE (Drug) $12.35
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.